Physician profile
Allison Cassedy
NPI 1083924963
$2,807.28
in general payments reported to CMS, 2019-2025
28 companies · $617 in 2025
The $617 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $511 · 2023: $379 · 2024: $679 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $434.22 | 2021-2025 | |
| Genzyme Corporation | $390.27 | 2021-2025 | |
| Pfizer INC. | $244.18 | 2021-2025 | |
| Ucb, INC. | $199.19 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $162.70 | 2022-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $139.59 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $134.16 | 2021-2025 | |
| Incyte Corporation | $107.87 | 2022-2025 | Opzelura |
| Almirall LLC | $96.29 | 2021-2022 | |
| Biofrontera INC. | $82.37 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Vyne Pharmaceuticals INC. | $79.61 | 2021 | |
| Organon LLC | $68.13 | 2025 | |
| Dermavant Sciences, INC. | $66.19 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $56.94 | 2021-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $52.67 | 2022-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.20 | 2023-2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $49.76 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $48.32 | 2021-2022 | |
| Leo Pharma INC. | $43.58 | 2022-2023 | Adbry |
| Kerecis Limited | $42.20 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Amgen INC. | $39.85 | 2021 | |
| Mayne Pharma Commercial LLC | $37.97 | 2021-2022 | |
| Organogenesis INC. | $37.32 | 2024 | Affinity |
| Journey Medical Corporation | $24.92 | 2023 | |
| Janssen Biotech, INC. | $20.13 | 2024 | Tremfya |
| Genentech USA, INC. | $18.97 | 2021 | |
| Nabriva Therapeutics, Plc | $16.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Cassedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.